TBX4Life

TBX4Life is a biotechnology company focused on developing gene therapies for patients with TBX4 syndrome and related pulmonary conditions. The company targets mutations in the T-box transcription factor 4 (TBX4) gene, which are known to cause a spectrum of disorders including childhood-onset pulmonary arterial hypertension and small patella syndrome. By utilizing advanced genetic engineering approaches, TBX4Life aims to restore functional TBX4 expression to treat the underlying cause of these rare and often life-threatening diseases. Their research is primarily centered on addressing the high unmet medical need in pediatric populations suffering from developmental lung defects.